Education

Select Language

English

Youth must also be educated on the importance of optimal disease management activities inclusive of taking prescribed medications, drinking fluids, avoiding extreme changes in temperature, eating a well-balanced diet, and engaging in behaviors that help prevent infections (e.g. hand washing, avoiding children who are sick).

It is also important to note that individuals with sickle cell disease are not cut out for strenuous, physical work- as such, emphasis must be placed on excelling academically.

For school-related resources on sickle cell disease, visit: https://sicklecellanemia.ca/schools

This page is dedicated to youth in their journey with sickle cell disease.

STORIES

Discover other Articles

SCAGO

Apr 8, 2025

Lack of Adequate Information on Insurance Policies Provided to International Students with Chronic Illnesses

Unclear health insurance coverage is a daunting reality for thousands of international students yearly.

SCAGO

Apr 8, 2025

Lack of Adequate Information on Insurance Policies Provided to International Students with Chronic Illnesses

Unclear health insurance coverage is a daunting reality for thousands of international students yearly.

SCAGO

Apr 8, 2025

Lack of Adequate Information on Insurance Policies Provided to International Students with Chronic Illnesses

Unclear health insurance coverage is a daunting reality for thousands of international students yearly.

SCAGO

Sep 26, 2024

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

SCAGO

Sep 26, 2024

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

SCAGO

Sep 26, 2024

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

Sep 27, 2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Sep 27, 2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Sep 27, 2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.